Here are five details.
1. In the first quarter, InVivo experiences a net loss of $4.8 million compared to a $6.4 million net loss in the same period in 2017.
2. Decreases in operating expenses allowed for a smaller net loss. The company reported $2 million in research and development expenses in the first quarter of 2018.
3. At the end of the quarter, InVivo had $11.6 million in cash and cash equivalents on hand.
4. During the first quarter, InVivo named Richard Toselli, MD, its president and CEO. He is a board-certified neurosurgeon.
5. InVivo also entered into a common stock purchase agreement with Lincoln Park Capital Fun to sell up to $15 million in shares of common stock to Lincoln Park.
More articles on devices and implants:
SeaSpine reports $33.2M in 2018 Q1 revenue: 6 things to know
Life Spine launches new SI joint fixation website: 4 highlights
RTI Surgical reports $69.9M in Q1 2018 revenues: 5 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
